Bethany C. Kennedy

Statistics

Publications

Citations

338

H-Index

Active since

2022

Affiliations

AstraZeneca (United Kingdom)(Current)

University of Cambridge

University of Birmingham

AstraZeneca (United States)

Wellcome Sanger Institute

Bethany C. Kennedy is an author at AstraZeneca (United Kingdom) specializing in cancer immunology, tumor immune microenvironment, and cancer immunotherapy.

ORCID

Publications per year

2022–2024

Publications

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity

Isaac Dean, Colin Y.C. Lee, Zewen Kelvin Tuong et al. · Nature Communications · 2024 · 168 citations · Full text

Life Sciences, Immunology, Oncology +14

In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue

Zhi Li, Zewen Kelvin Tuong, Isaac Dean et al. · The Journal of Experimental Medicine · 2022 · 113 citations · Full text

Medicine, Immunology, Oncology +17

Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

Colin Y.C. Lee, Bethany C. Kennedy, Nathan Richoz et al. · Nature Communications · 2024 · 57 citations · Full text

Life Sciences, Immunology, Oncology +13

1–3 of 3